Gonadorelin (10mg)

Pituitary Gonadotropin Release:

Stimulates synthesis and secretion of LH and FSH in vitro and in vivo via activation of GnRH receptors, facilitating controlled experimental modulation of the HPG axis [2][3][4]. 

Pulsatile Secretion Modeling:

Due to its short half-life, Gonadorelin requires pulsatile or repeated dosing to mimic physiological GnRH pulses, a property leveraged in research protocols [4]. 

Reproductive Endocrine Studies:

Extensively utilized to examine reproductive hormone dynamics, including studies on ovulation induction, testosterone regulation, and fertility signaling in diverse mammalian models [3][5]. 

Endocrine Feedback Investigations:

Serves as a tool to study negative feedback loops involving sex steroids and inhibin, particularly in models of endocrine disorders and aging [5]. 

Cancer Research Application:

In laboratory models such as hormone-responsive prostate cancer cell lines, GnRH receptor-targeted agents like Gonadorelin are being explored for selective cellular targeting and antiproliferative activity [6]. 

Citations

1. PubChem Compound Summary for Gonadorelin (CID 36523): decapeptide pGlu–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly–NH₂; formula C₅₅H₇₅N₁₇O₁₃; MW 1,182 Da. 
2. RxReasoner Overview: Gonadorelin stimulates LH and FSH synthesis and release in anterior pituitary models; formula and pharmacokinetic data. 
3. Limonta P, et al. Exploration of GnRH receptor roles in cancer cell models; GnRH analogues regulate neuroendocrine and tumor pathways. Endocr. Rev. 2012;33(5):784–811. PMID: 22826366. 
4. DrugBank Entry for DB00644: pharmacodynamics of Gonadorelin—pulsatile release requirement; short half-life (10–40 min); GnRH receptor agonism. 
5. Zhang G, et al. Hypothalamic programming of systemic aging involving GnRH modulation. Nature. 2013;497(7448):211–215. PMID: 23619691. 
6. Maleksabet A, et al. Gonadorelin–ribonuclease fusion induces apoptosis in GnRH-receptor–positive prostate cancer cells in vitro. Oncol. Lett. 2023;26(1):Article 45. PMID: 36748250.